Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis

Cancer Science

Volumn 102, Issue 4, 2011, Pages 776-783

  Shio, Seiji ^a   Kodama, Yuzo ^a   Ida, Hiroshi ^a   Shiokawa, Masahiro ^a   Kitamura, Koji ^a   Hatano, Etsuro ^a   Uemoto, Shinji ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; PROTEIN P21; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA; VORINOSTAT;

ARTICLE; BILIARY TRACT CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACETYLATION; BILIARY TRACT NEOPLASMS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 3 SUBUNIT; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 79952768248     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01848.x     Document Type: Article

References (22)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-25.
2. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-21.
3. de Gron PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 1368-78.
4. Ito Y. Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells 1999; 4: 685-96.
5. Levanon D, Berstein Y, Negreanu V et al. A large variety of alternatively spliced and differentially expressed mPNAs are encoded by the human acute myeloid leukemia gene AML1. DNA Cell Biol 1996; 15: 175-85.
6. Li QL, Ito K, Sakakura C et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-24.
7. Hasegawa K, Yazumi S, Wada M et al. Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line. Cancer Sci 2007; 98: 838-43.
8. Chi XZ, Yang JO, Lee KY et al. RUNX suppresses gastric epithelial cell growth by inducing p21(WAF/Cip1) expression in cooperation with transforming growth factor beta -activated SMAD. Mol Cell Biol 2005; 25: 8097-107.
9. Yano T, Ito K, Fukamachi H et al. RUNX3 tumor suppressor upregulates Bim in gastric epitherial cells undergoing transforming growth factor beta-inducede apoptosis. Mol Cell Biol 2006; 26: 4474-88.
10. Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605-15.
11. Wada M, Yazumi S, Takaishi S et al. Frequent loss of RUNX3 geneexpression in human bile duct and pancreatic cancer cell lines. Oncogene 2004; 23: 2401-7.
12. Li QL, Kim HR, Kim WJ et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004; 314: 223-8.
13. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003; 94: 589-92.
14. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 376-80.
15. Kim TY, Lee HJ, Hwang KS et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004; 84: 479-84.
16. Goel A, Arnold CN, Tassone P et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004; 112: 754-9.
17. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233-40.
18. Huang C, Ida H, Ito K, Zhang H, Ito Y. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol 2007; 73: 990-1000.
19. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
20. Kumagai T, Wakimoto N, Yin D et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121: 656-65.
21. Miyazaki M, Ohashi R, Tsuji T, Mihara K, Gohda E, Namba M. Transforming growth factor-beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1. Biochem Biophys Res Commun 1998; 246: 873-80.
22. Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001; 20: 3156-65. Review.